Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06565637 · ClinicalTrials.gov registry record · Phase 1

Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals With Eating Disorders

A Phase 1 study of Eating Disorders and Sexual Minorities, sponsored by Auburn University.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT06565637: Recruiting Phase 1 study of Eating Disorders and Sexual Minorities, sponsored by Auburn University.

NCT06565637 is a Phase 1 study of Eating Disorders and Sexual Minorities that is actively recruiting participants, run by Auburn University. The registered enrollment target is 30 participants, below the 322-participant average among 37 other Eating Disorders trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06565637, a Phase 1 study of Eating Disorders and Sexual Minorities, is actively recruiting participants, sponsored by Auburn University.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to learn if a new intervention (Promoting Resilience to Improve Disordered Eating; PRIDE) can decrease internalized stigma and increase the ability to cope effectively with stressors in sexual minority populations diagnosed with eating disorders. The main question it aims to answer is: Will an eating disorders treatment focused on decreasing internalized stigma and increasing sexual minority stress coping self efficacy in sexual minority populations? Participants Will * Complete a telephone screen with study staff to determine preliminary eligibility for the study * Undergo a behavioral eligibility screening that includes structured clinical interviewing in order to determine proper diagnosis of an eating disorder along with ensuring absence of non-eating disorder diagnoses * Complete self-report measures to determine study eligibility * Attend up to 14 weekly therapy sessions as part of the PRIDE intervention, where participants will work with qualified clinicians to address eating pathology and disordered body image along with developing effective strategies for coping with sexual minority stressors * Complete surveys upon completion of the intervention 3 and 6 months post follow-up

Primary Outcome

Assesses internalized stigma (9 items, 5-point scale, higher scores indicate greater internalized stigma).

Interventions

  • BEHAVIORAL Promoting Resilience to Improve Disordered Eating

Study Locations (2)

Alabama

  • Auburn University - Auburn

California

  • San Diego State University - San Diego

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-02-28
Est. Completion 2026-07-01
Phase Phase 1
Auburn University

54 total trials

What NCT06565637 shows while recruiting

NCT06565637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 322-participant average among 37 other Eating Disorders trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Eating Disorders appearing as the primary indexed condition, and to 1 intervention - of which Promoting Resilience to Improve Disordered Eating is the first listed.

NCT06565637 reports a single indexed study location in Alabama, California.

Frequently Asked Questions

What is clinical trial NCT06565637 about?

NCT06565637 is a clinical study titled "Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals With Eating Disorders". The goal of this clinical trial is to learn if a new intervention (Promoting Resilience to Improve Disordered Eating; PRIDE) can decrease internalized stigma and increase the ability to cope effectively with stressors in sexual minority populations diagnosed with eating disorders. The main question ...

What is the current status of trial NCT06565637?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-02-28. Estimated completion is 2026-07-01.

What conditions does trial NCT06565637 study?

This clinical trial studies the following conditions: Eating Disorders, Sexual Minorities.

What interventions are being tested in trial NCT06565637?

The interventions under investigation include: Promoting Resilience to Improve Disordered Eating (BEHAVIORAL).

Who is sponsoring clinical trial NCT06565637?

This trial is sponsored by Auburn University, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06565637 being conducted?

This trial has 2 study locations across Alabama, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eating Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06565637's enrollment target sits among peer trials

30 32nd of 37 higher than 4 of 37 other Eating Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Eating Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06565637, the US trial registry maintained by the National Library of Medicine. NCT06565637 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.